Voya Investment Management LLC grew its position in iRhythm Technologies (NASDAQ:IRTC - Free Report) by 3,578.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 230,934 shares of the company's stock after purchasing an additional 224,656 shares during the period. Voya Investment Management LLC owned about 0.70% of iRhythm Technologies worth $26,248,000 at the end of the most recent reporting period.
Several other hedge funds also recently bought and sold shares of the company. Versant Capital Management Inc grew its holdings in shares of iRhythm Technologies by 123.2% in the 3rd quarter. Versant Capital Management Inc now owns 221 shares of the company's stock valued at $25,000 after buying an additional 122 shares during the period. Covestor Ltd increased its position in shares of iRhythm Technologies by 44.8% in the 3rd quarter. Covestor Ltd now owns 417 shares of the company's stock valued at $47,000 after buying an additional 129 shares in the last quarter. Rothschild Investment LLC increased its position in shares of iRhythm Technologies by 170.0% in the 3rd quarter. Rothschild Investment LLC now owns 216 shares of the company's stock valued at $25,000 after buying an additional 136 shares in the last quarter. Assetmark Inc. increased its position in shares of iRhythm Technologies by 30.1% in the 1st quarter. Assetmark Inc. now owns 821 shares of the company's stock valued at $97,000 after buying an additional 190 shares in the last quarter. Finally, Global Retirement Partners LLC raised its stake in iRhythm Technologies by 5,450.0% during the 3rd quarter. Global Retirement Partners LLC now owns 222 shares of the company's stock worth $25,000 after buying an additional 218 shares during the period.
iRhythm Technologies Stock Up 0.5%
iRhythm Technologies stock opened at $94.72 on Friday. The stock has a market capitalization of $3.18 billion, a PE ratio of -80.96 and a beta of 1.39. iRhythm Technologies has a twelve month low of $82.85 and a twelve month high of $192.47. The company has a quick ratio of 3.45, a current ratio of 3.57 and a debt-to-equity ratio of 3.68. The company has a 50 day moving average of $109.28 and a 200-day moving average of $118.36.
iRhythm Technologies (NASDAQ:IRTC - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported $0.82 EPS for the quarter, topping analysts' consensus estimates of $0.02 by $0.80. iRhythm Technologies had a negative net margin of 4.52% and a positive return on equity of 26.88%. The business had revenue of $221.59 million for the quarter, compared to analyst estimates of $222.23 million. During the same period last year, the business posted ($0.06) earnings per share. The firm's quarterly revenue was up 14.9% on a year-over-year basis. On average, equities research analysts anticipate that iRhythm Technologies will post 0.79 EPS for the current fiscal year.
iRhythm Technologies declared that its board has authorized a stock repurchase program on Wednesday, November 11th that permits the company to repurchase $200 million in shares. This buyback authorization permits the company to purchase up to 6.7% of its shares through open market purchases. Share buyback programs are usually a sign that the company's board of directors believes its stock is undervalued.
Analysts Set New Price Targets
Several research analysts have weighed in on IRTC shares. Stephens reduced their target price on iRhythm Technologies from $160.00 to $120.00 and set an "overweight" rating on the stock in a report on Wednesday, November 11th. Wells Fargo & Company lowered their price target on iRhythm Technologies from $150.00 to $135.00 and set an "overweight" rating for the company in a report on Friday, November 6th. Weiss Ratings downgraded iRhythm Technologies from a "sell (d-)" rating to a "sell (e+)" rating in a report on Thursday, November 12th. JPMorgan Chase & Co. dropped their price target on iRhythm Technologies from $175.00 to $145.00 and set an "overweight" rating on the stock in a research report on Friday, November 6th. Finally, Truist Financial dropped their price target on iRhythm Technologies from $168.00 to $140.00 and set a "buy" rating on the stock in a research report on Monday, November 9th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $164.07.
Get Our Latest Report on IRTC
Insider Transactions at iRhythm Technologies
In other news, Director Abhijit Talwalkar purchased 7,900 shares of the company's stock in a transaction on Thursday, November 19th. The shares were purchased at an average price of $96.67 per share, with a total value of $763,693.00. Following the purchase, the director directly owned 7,900 shares of the company's stock, valued at $763,693. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.98% of the company's stock.
iRhythm Technologies Company Profile
(
Free Report)
iRhythm Technologies is a medical technology company that develops digital solutions for detecting and monitoring heart rhythm disorders. Its services combine wearable electrocardiogram (ECG) devices with cloud-based data analysis and clinical reporting to help healthcare professionals assess patients for conditions such as cardiac arrhythmias. The company's Zio product line includes wearable ECG monitors, such as Zio XT, which records a patient's heart activity during an extended monitoring period. iRhythm also offers Zio AT, a monitoring service designed to provide clinicians with ECG data during the monitoring period.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider iRhythm Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iRhythm Technologies wasn't on the list.
While iRhythm Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.